###### Strengths and limitations of this study

-   Randomised, double-blind, placebo-controlled study design.

-   Multicentre trial.

-   Sufficient sample size and follow-up.

-   Novel intervention.
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-   Surrogate end points, no hard clinical endpoints, for example, cardiovascular events or mortality.

-   Unknown whether results can be extrapolated to more severe forms of kidney disease.

Introduction {#s1}
============

Chronic kidney disease (CKD) is prevalent in approximately 13% of the general population[@R1] and is associated with an increased risk of developing cardiovascular disease (CVD).[@R2] This is partly due to an accumulation of traditional CVD risk factors (eg, hypertension, dyslipidaemia, diabetes mellitus (DM), age), but even after adjusting for these risk factors, CKD is still associated with an increased risk of CVD as compared with the general population.[@R2] This implies that other non-traditional CVD risk factors associated with CKD are causing an increased risk of CVD. Vascular calcification (VC) is highly prevalent among persons with CKD[@R3] and is thought to be partly responsible for this increased risk of CVD. Indeed, indirect measurements of VC (eg, coronary artery calcifications score (CAC), pulse wave velocity (PWV) and pulse pressure) have been associated with increased risk of CVD (particularly heart failure) in persons with CKD.[@R4] Thus, any intervention that could prevent the development or progression of VC is presumed also to reduce the risk of CVD and death.

In subjects with CKD, disturbances in the mineral and bone metabolism are thought to be one of the main causes of VC. As kidney function declines, phosphate (PO~4~) accumulates in serum and binds to calcium (Ca). Once the concentration of Ca/PO~4~ particles in serum exceed their saturation point, they precipitate and induce the vascular smooth muscle cells (VSMC) of the arteries to undergo a dedifferentiation into an osteogenic phenotype in which the VSMC calcify and stiffen.[@R7] So far, efforts to prevent VC in CKD have been focused on the concentration of calcification promoters in serum (ie, PO~4~ and Ca), but recently focus has shifted to also consider the concentration of calcification inhibitors in serum. *In vitro* studies of PO~4~-induced VC and animal studies of CKD and VC have consistently shown that increasing magnesium (Mg) levels prevents or reduces the development of VC[@R8] by increasing the expression of intracellular calcification inhibitors and decreasing the expression of calcification promoters and PO~4~ transporters. Several epidemiological studies have shown that higher levels of serum Mg are associated with improved survival in patients with CKD[@R16] and end-stage renal disease (ESRD).[@R17] Also, higher levels of serum Mg are associated with reduced incidence and progression of CKD[@R25] and with lower prevalence of VC in CKD.[@R28]

In this setting, increasing the Mg concentration in serum by means of Mg supplementation is an attractive prospect. Two small clinical trials of Mg supplementation in ESRD have shown that this intervention can reduce the progression of carotid intima/media thickness (a proxy for VC) with no incidences of toxic hypermagnesaemia.[@R29] So far, no clinical trials have investigated the effect of Mg supplementation on VC in predialysis CKD. We therefore posed the research question of whether Mg supplementation is effective in preventing the progression of VC in CKD.

In this paper, we will describe the design and rationale of our randomised placebo-controlled double-blinded multicentre clinical trial designed to investigate whether 52 weeks of treatment with oral Mg supplementation can prevent the progression of CAC in subjects with CKD stage 3b-4.

Methods and analysis {#s2}
====================

Study design and population {#s2a}
---------------------------

This trial is an investigator-initiated double-blind placebo-controlled multicentre clinical trial being performed at 10 sites in departments of nephrology in Denmark and Norway. We will include adult persons with CKD stage 3b-4 whom we consider to be at increased risk of VC based on serum Mg and PO~4~. The full list of inclusion and exclusion criteria is shown in [figure 1](#F1){ref-type="fig"}.
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Study intervention {#s2b}
------------------

The subjects participating in the trial will be randomised in a ratio of 1:1 to 52 weeks treatment with either oral slow-release Mg hydroxide (Mablet 360 mg, Gunnar Kjems, Denmark) twice daily or matching placebo twice daily ([figure 2](#F2){ref-type="fig"}). Mablet is used for Mg supplementation and one tablet containing 360 mg of Mg hydroxide is equivalent to 15 mmol of elemental Mg, and the intervention will therefore consist of a daily dose of 30 mmol of elemental Mg. Mg hydroxide and placebo tablets are identical in appearance, odour, constituents and containers and do not contain calcium. The study medication has been packed in consecutively numbered containers according to a computer-generated randomisation list and will be administered to subjects consecutively as they enter the trial. The randomisation will be stratified based on enrolment site and DM. Both subjects and investigators will be blinded to the study medication during the course of the trial.
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Study visits {#s2c}
------------

All persons being followed in the outpatient clinics at the participating sites will be screened for eligibility prior to their planned appointments in the clinics and offered participation in the trial.

At week 0, subjects will give written informed consent to participate in the trial, and will have their relevant medical history recorded along with anthropomorphic measurements. After this, they will undergo a multislice ECG gated CT scan of the coronary arteries of their heart to calculate the extent of any VC based on CAC by the Agatston method.[@R31] In addition, subjects will have fasting blood samples drawn for assessment of kidney function, electrolytes, mineral metabolism and serum calcification propensity (T~50~).[@R32] Samples from a 24-hour urine collection will be collected to assess urinary excretion of minerals and protein, and a resting ECG will be performed to assess length of the PQ interval and the corrected QT interval (QT~c~). At selected sites, subjects will also undergo measurement of bone mineral density (BMD) of their lumbar vertebrae and hip during their CT scan, and arterial tonometry will be performed to assess carotid-femoral PWV (CF-PWV) and radial PWA (see [figure 3](#F3){ref-type="fig"} for the full list of assessments at study visits).
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Following the baseline visit, each subject will be seen for follow-up visits at 13-week intervals (ie, week 13, week 26 and week 39), at which times subjects will have fasting blood samples drawn to assess safety of the intervention (see the Safety monitoring section), 24 hours urine collections will be sampled to assess mineral excretion and study medication will be dispensed. Adherence to the intervention will be assessed by pill count of any remaining study medication from the previous study visit.

At the final study visit (week 52), subjects will repeat baseline measurements, after which they will return to their regular outpatient care.

Safety monitoring {#s2d}
-----------------

All subjects will have serum Mg and potassium evaluated at each follow-up visit and will be questioned on any potential side effects to the treatment, particularly gastrointestinal side effects such as loosening of stool or diarrhoea. If at any time serum Mg exceeds 1.80 mmol/L, the subject will cease study medication, and a follow-up blood sample for serum Mg will be drawn 2 weeks later. If at this time serum Mg still exceeds 1.50 mmol/L, the subject will permanently cease study medication, but will otherwise continue in the trial as planned. If serum Mg does not exceed 1.50 mmol/L the subject will continue study medication at half dose (ie, only take study medication once daily) and a follow-up blood sample for serum Mg will be drawn again 2 weeks later. If at this time serum Mg exceeds 1.50 mmol/L, the subject will permanently cease study medication, but will otherwise continue in the trial as planned. Any incidences of hyperkalaemia will be handled at the discretion of the local site investigator.

Adverse events and serious adverse events will be recorded and reported to an independent data and safety monitoring board.

Concomitant medical therapy {#s2e}
---------------------------

Subjects should not initiate treatment with Mg-containing medication, laxatives or antacids during the trial. Also, investigators should avoid initiating medical therapy that might reduce Mg absorption in the gut or Mg loss in the kidneys. Therefore, investigators should avoid initiating proton pump inhibitors unless necessary for serious gastrointestinal conditions (histamine H~2~-receptor antagonist may be considered as an alternative), and if possible investigators should not initiate or increase doses of thiazide diuretics, thiazide-like diuretics or loop diuretics for treatment of hypertension and should instead use other antihypertensive agents. All medications and any changes to these will be recorded at baseline and at each follow-up visit.

Study end points {#s2f}
----------------

The primary end point of this trial is the difference in change of CAC score from week 0 to week 52 between the two groups. CAC scores will be calculated independently by two observers trained in CAC scoring. In the event of \>5% difference in calculated CAC score, the score will be recalculated by both observers together for a final CAC score. Subgroup analyses will be performed to assess the effect of the intervention on CAC progression in subjects with and without DM, in subjects with CAC \>0 and CAC=0 at baseline and in subjects divided into tertiles of T~50~.

Secondary end points include change and CF-PWV and PWA, change in BMD, change in markers of mineral metabolism, difference in rate of estimated glomerular filtration rate (eGFR) decline, as well as clinical end points such as incidence of major adverse cardiovascular events (myocardial infarction, stroke, new-onset heart failure or hospitalisation for heart failure and limb amputation or revascularisation due to peripheral arterial occlusion), all-cause and cardiovascular mortality, adverse and serious adverse events and incidence of ESRD (defined as dialysis initiation or kidney transplantation). In addition, subjects will be contacted 5 years after their participation in the study to assess whether Mg supplementation reduces the incidence of major adverse cardiovascular events, death or ESRD.

Statistical analysis {#s2g}
--------------------

Data that follow a normal distribution will be described as mean±SD and non-normal data will be described as median with IQR. The primary end point will be compared between the two treatment groups using an unpaired Student's t-test (possibly after logarithmic transformation if the data do not follow a normal distribution) and as intention to treat. Changes and between-group differences in secondary end points will be analysed using paired and unpaired Student's t-tests or Wilcoxon and Mann-Whitney tests for continuous variables and χ^2^ or Fisher's exact test for dichotomous variables. Linear mixed models will be used to analyse variables with repeated measures. Linear and logistic regression analyses with adjustment for various covariates will be applied to baseline data to investigate any associations with the change in various parameters as well as any associations with clinical events.

The data analysis will be performed blinded to the treatment allocation.

Sample size calculation {#s2h}
-----------------------

In a prospective observational study of 53 patients with CKD stage 3--5, 27 patients (51%) had CAC at baseline.[@R33] Of these 27 patients, the annual progression of CAC score was 275.6±69.2 (mean and SE of the mean). The SD at baseline for CAC score in this group of 27 patients was 360. We consider an annual difference in CAC score of 200 to be the minimally relevant difference, since a difference in change of this magnitude has been shown in a previous trial of phosphate binder treatment in CKD stage 3--5.[@R34] With a power (β) of 20% in a two-sample t-test with a significance (α) of 5% the sample size must be 52 per group, when considering only the data concerning the patients who had CAC at baseline. However, since we do not know whether subjects will have CAC or not at baseline, we must assume that the prevalence (51%) and progression of CAC in our population will be similar to the reference study. Based on this, we therefore need 108 subjects per group. We anticipate a dropout rate of 15%, and the trial will therefore include 250 subjects randomised in a ratio of 1:1.

Ethics and dissemination {#s2i}
------------------------

All subjects will give written informed consent prior to initiating the trial and the trial will be performed according to the lasted revision of the Helsinki Declaration. We applied for and received approval to conduct the trial from the Danish and Norwegian National Committees on Biomedical Research Ethics (H-15009846 and REK Sør-Øst D 2015/2428, respectively) as well as the Danish and Norwegian Data Protection Agencies (2012-58-0004 and 16--077, respectively). Since Mablet is registered as a supplement and not a drug, the trial does not require approval from the Danish or Norwegian medical agencies. We have established an independent data safety monitoring board at Nordsjællands Hospital, Hillerød, Denmark, which will monitor all serious adverse events occurring during the trial. Lastly, we registered the trial at [www.clinicaltrials.gov](www.clinicaltrials.gov) (NCT02542319) prior to initiating the trial.

We began recruitment in December 2015 and expect to have completed recruitment by September 2017 and completed data collection by September 2018. The final results of the trial will be published in international peer-reviewed journals.

Discussion {#s3}
==========

Assessing risk of VC progression {#s3a}
--------------------------------

Serum PO~4~ is the only modifiable risk factor that has been associated with progression of CAC in predialysis CKD,[@R33] and all published in vitro and animal studies of Mg in PO~4~-induced VC have shown that Mg ameliorates the development of VC.[@R8] Thus, PO~4~ likely promotes CAC progression in CKD, and increasing levels of Mg seem to prevent VC induced by PO~4~. Therefore, it seems reasonable to consider patients with 'increased' PO~4~ and 'reduced' levels of Mg to be at risk of CAC progression.

In a previous randomised clinical trial of CAC progression in patients with predialysis CKD and no history of coronary artery disease, previous stroke, DM or dyslipidaemia (ie, free of important conventional risk factors associated with VC and thus reflecting 'uremic' causes of VC), the placebo group had a mean serum PO~4~ of 1.26 mmol/L at baseline and experienced an annual progression of CAC by approximately 200.[@R34] Unfortunately, no trials in predialysis CKD have examined the quantitative role of Mg in CAC progression. However, one cross-sectional study found that for PO~4~ \<1.10 mmol/L there was no relationship between serum Mg and CAC density, while for PO~4~ \>1.10 mmol/L there was an almost linear inverse relationship between serum Mg and CAC density.[@R28] Based on this, we have made the assumptions that serum PO~4~ \>1.10 mmol/L is necessary for serum Mg to exert its calcification inhibitory effects, and serum PO~4~ \>1.26 mmol/L is predictive of CAC progression when serum Mg is unknown. We have therefore semiarbitrarily set our threshold for risk of CAC progression at serum Mg \<0.82 (ie, below the mean laboratory value of Mg) when serum PO~4~ \>1.15 mmol/L, or serum Mg \<0.92 (ie, below the upper laboratory limit of Mg) when serum PO~4~ \>1.30 mmol/L.

We acknowledge that several other factors involved in mineralisation are likely involved in the propensity towards CAC, and that our assumption does not account for these. However, there is no available evidence linking these other factors with risk of CAC progression and most are not implemented in clinical practice. Therefore, we have chosen a pragmatic approach to assessment of VC risk based only on serum PO~4~ and Mg.

Safety and efficacy of Mg supplementation {#s3b}
-----------------------------------------

Prior to the design of this trial, we conducted a randomised double-blind placebo-controlled clinical trial to examine the safety and efficacy of 8 weeks of slow-release Mg hydroxide supplementation in subjects with eGFR \<60 mL/min/1.73 m^2^ and low or low-normal serum Mg, and found that a dose of 30 mmol/day was necessary to achieve statistically significant increases in serum Mg.[@R35] This intervention was found to be safe (ie, no incidences of serum Mg\>2.0 mmol/L) and the incidences of gastrointestinal side effects were similar to placebo treatment. Also, this intervention increased T~50~, which is believed to reflect the propensity towards ectopic calcification and which has been shown to be inversely associated with all-cause mortality in a predialysis CKD.[@R36] The pilot trial was small and of only 8 weeks duration, so it is possible that there are side effects or toxicities related to the chosen dose of Mg supplementation, which will only become manifest after longer treatment periods.

We chose the slow-release Mg hydroxide formulation used in this trial because it is cheap and widely available in Denmark. Due to its slow-release formulation, it does not have the laxative effect usually associated with inorganic Mg compounds, although long-term use or high doses are known to cause loosening of stool and/or frequent bowel movements. It is possible that other organic Mg formulations (eg, Mg citrate) might have greater bioavailability of Mg[@R37] and fewer gastrointestinal side effects, but to our knowledge no clinical trials have examined their safety and efficacy in subjects with CKD.

Mg supplementation as a PO~4~ binder {#s3c}
------------------------------------

Given the known PO~4~-lowering effects of Mg-containing PO~4~ binders,[@R39] it is possible that the Mg supplementation used in this trial might also reduce serum PO~4~. We found no effect of Mg supplementation on serum PO~4~, 24 hours urine PO~4~ or intact fibroblast growth factor 23 in our previously mentioned trial of Mg supplementation, suggesting that the Mg formulation used in this trial does not act as a PO~4~ binder.[@R35] The size and duration of this trial will make it possible to better assess any effects of Mg supplementation on PO~4~ homeostasis, although any results must be interpreted with caution, since this trial is not designed to address this research question.

Limitations of this trial {#s3d}
-------------------------

The main limitation of this trial is that CAC is only a surrogate measure for CVD. Even if Mg supplementation is effective in reducing the progression of CAC, this trial is not powered to assess whether reduced progression of CAC reduces the incidence of cardiovascular events or mortality.

Although intimal and medial calcification often occur simultaneously, calcification due to disturbances in mineral and bone metabolism is believed mainly to cause medial calcification. CAC by the Agatston method measures the product of volume and density of calcium in the coronary arteries but cannot differentiate between intimal and medial calcification, and thus it is not possible to assess whether any changes to CAC are due to intimal calcification, medial calcification or both. Mg supplementation might also reduce progression of aortic calcification and thereby progression of aortic stiffness, in which case CF-PWV might be affected by the intervention. CF-PWV will be measured in a subset of the subjects participating in the trial.

A further limitation of this trial is that the trial will only include subjects with CKD stage 3b-4. Patients with stage 5 CKD will likely have greater risk of VC progression and would therefore potentially have greater benefit of any treatment effect. However, since there are no clinical trials assessing the safety of Mg supplementation in stage 5 CKD, we have excluded patients with eGFR \<15 mL/min/1.73 m^2^ from this trial. It is likely that some subjects will progress to stage 5 CKD during the course of the trial, and if any of these subjects are randomised to Mg supplementation, we will learn more about the safety of Mg supplementation in subjects with very low eGFR.

Potential impact of the trial {#s3e}
-----------------------------

Previous trials have examined the effect of PO~4~ binders on progression of VC in predialysis CKD with varying results.[@R34] This trial tests a new approach to the prevention of VC, by attempting to increase the uptake of a calcification inhibitor instead of limiting the uptake of a calcification promoter. If successful, this trial might pave the way for larger randomised clinical trials investigating the effects of Mg supplementation on cardiovascular events and all-cause mortality. Mg supplementation is cheap and widely available, which would make this intervention accessible and affordable to all patients with CKD.
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